Takeda
Last updated Jun 19, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
5
Clinical Programs
0
Confidence Coverage
68%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- Colorectal Cancer
Highest priority development: Oncology (Cancer)/Hematologic Malignancies Approval Notifications
Regulatory precedent
Why this matters: sets a approval precedent in the same sub-indication (colorectal cancer) as Takeda.
Competitive pressure: Low
Portfolio impact: Low
Evidence coverage: 68%
Active Signals
1
Investigate Priority
0
Opportunity Score
16
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 19, 2026Score 16Fruquintinib Study in Metastatic Colorectal Cancer Patients in Poland
Oncology · Colorectal Cancer
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- Oncology (Cancer)/Hematologic Malignancies Approval NotificationsLow Confidence · 54%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Sunscreen: How to Help Protect Your Skin from the SunModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and DeathModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and AnswersModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Takeda right now?
- Which regulatory precedents should Takeda monitor in Oncology and Colorectal Cancer?
- How does Emerging Clinical Trials in Oncology compare to the nearest competitive programs?
- What signals require immediate investigation for Takeda?
- Summarize the strategic implications of recent developments for Takeda.
- Where is the greatest uncertainty in Takeda's competitive positioning?